Organon launches as new global women’s health company and appoints leaders in Latin America

Home/Pharma News | Posted 23/07/2021 post-comment0 Post your comment

Organon celebrated its launch as a global women’s health company on 3 June 2021 with employees and women from around the world, as the Organon executive leadership team rings the opening bell at the New York Stock Exchange.

Follitropin V13I20

Organon is a global healthcare company formed through a spinoff from Merck, known as MSD outside of Canada and the US, to focus on improving the health of women throughout their lives. In addition, Organon is pursuing opportunities to collaborate with biopharmaceutical innovators looking to commercialize their products by leveraging its scale and presence in fast growing international markets.

In June 2021, Organon appointed Julio Cesar Conejero as General Manager in Latin America, Juan Patricio Clark as Business Director in Colombia and Fernando Fogarin, Executive Director in Mexico.

Organon’s portfolio will consist of more than 60 medicines and products across an international footprint that serves people in more than 140 markets, with nearly 80% of its approximately US$6.5 billion in annual revenue generated outside the US.

The company has three core pillars that will benefit from renewed management focus and commercial investment: women’s health, biosimilars and established brands.

Biosimilars are a key growth pillar with products available in various parts of the world, such as infliximab and etanercept in immunology and trastuzumab in oncology. Organon’s expertise is in the commercialization of these products, allowing their accessibility to more people worldwide.

Related articles
Biobadamérica promotes the use of biological and biosimilar drugs in Latin America

PlantForm and partners in Brazil to develop pembrolizumab biosimilar

LATIN AMERICAN FORUM

The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. 

View this week’s headline article: ¿Qué conduce a las percepciones negativas de los biosimilares?

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: ¿Qué conduce a las percepciones negativas de los biosimilares?

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

  
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

Source: Organon

comment icon Comments (0)
Post your comment
Related content
Licensing agreements signed for ustekinumab biosimilars
IBD 1
Home/Pharma News Posted 17/09/2021
Oncogen–BrightGene partnership
104 MD001918
Home/Pharma News Posted 10/09/2021
Menagen–CKD Middle Eastern partnership
01 AA007239
Home/Pharma News Posted 03/09/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010